DUONEB (albuterol sulfate; ipratropium bromide) by Teva is clinical pharmacology the prime action of beta-adrenergic drugs is to stimulate adenyl cyclase, the enzyme which catalyzes the formation of cyclic-3',5'-adenosine monophosphate (cyclic amp) from adenosine triphosphate (atp). Approved for bronchospasm associated with copd in patients requiring more than one bronchodilator, copd. First approved in 2001.
Drug data last refreshed 15h ago · AI intelligence enriched 2w ago
DUONEB is a fixed-dose combination inhaled solution containing albuterol sulfate (short-acting beta-2 agonist) and ipratropium bromide (anticholinergic) for acute bronchodilation. It treats bronchospasm associated with COPD in patients requiring dual bronchodilator therapy. The combination works by stimulating beta-2 adrenergic receptors and blocking muscarinic receptors to relax airway smooth muscle via complementary mechanisms.
Product approaching loss of exclusivity with minimal linked career activity; brand team likely focused on generic transition and retained market share retention.
CLINICAL PHARMACOLOGY The prime action of beta-adrenergic drugs is to stimulate adenyl cyclase, the enzyme which catalyzes the formation of cyclic-3',5'-adenosine monophosphate (cyclic AMP) from adenosine triphosphate (ATP). The cyclic AMP thus formed mediates the cellular responses. In vitro…
Worked on DUONEB at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moDUONEB offers limited career expansion given its LOE-approaching lifecycle stage and lack of pipeline activity. Roles are concentrated in market maintenance, provider relationship management, and generic transition planning rather than growth-oriented functions.